Peripheral hyperalgesic cytokines.
Cunha
Fernando Q
FQ
Departamento de Farmacologia, Campus da USP, Ribeirão Preto, SP, Brasil.
Ferreira
Sérgio H
SH
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001920:Bradykinin / Q000502:physiology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology*; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use; D015232:Dinoprostone / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D006358:Hot Temperature; D006801:Humans; D006930:Hyperalgesia / Q000188:drug therapy / Q000503:physiopathology*; D007375:Interleukin-1 / Q000494:pharmacology / Q000627:therapeutic use; D053583:Interleukin-1beta; D007378:Interleukins / Q000494:pharmacology / Q000502:physiology; D007527:Isoenzymes / Q000502:physiology; D008565:Membrane Proteins; D020932:Nerve Growth Factor / Q000494:pharmacology / Q000502:physiology; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D010147:Pain Measurement; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology; D051381:Rats; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000502:physiology
D000700:Analgesics; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D007375:Interleukin-1; D053583:Interleukin-1beta; D007378:Interleukins; D007527:Isoenzymes; D008565:Membrane Proteins; D010446:Peptide Fragments; D014409:Tumor Necrosis Factor-alpha; C056932:interleukin 1beta (193-195); D013792:Thalidomide; D003907:Dexamethasone; D020932:Nerve Growth Factor; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D001920:Bradykinin